RhoGDIα downregulates androgen receptor signaling in prostate cancer cells Article (Faculty180)

cited authors

  • Zhu, Yezi; Liu, Chengfei; Tummala, Ramakumar; Nadiminty, Nagalakshmi; Lou, Wei; Gao, Allen C


  • Treatment of primary prostate cancer (CaP) is the withdrawal of androgens. However, CaP eventually progresses to grow in a castration-resistant state due to aberrant activation of androgen receptor (AR). Understanding the mechanisms leading to the aberrant activation of AR is critical to develop effective therapy. We have previously identified Rho GDP Dissociation Inhibitor alpha (GDIα) as a novel suppressor in prostate cancer. In this study, we examine the effect of GDIα on AR signaling in prostate cancer cells.

publication date

  • 2013

published in

start page

  • 1614

end page

  • 22


  • 73